Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection

Cancer

Volumn 119, Issue 1, 2013, Pages 126-135

  Li, Tao ^a   Qin, Lun Xiu ^b   Gong, Xiao ^c   Zhou, Jian ^b   Sun, Hui Chuan ^b   Qiu, Shuang Jian ^b   Ye, Qing Hai ^b   Wang, Lu ^b   Fan, Jia ^b  

^a SHANDONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

hepatitis; hepatocellular carcinoma; prognosis; recurrence; risk factors

Indexed keywords

ALPHA FETOPROTEIN; ESTROGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C ANTIBODIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84872816209     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27697     Document Type: Article

References (42)

1. Hassoun Z, Gores GJ,. Treatment of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2003; 1: 10-18.
2. Omata M, Yoshida H, Shiratori Y,. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol. 2005; 3 (10 suppl 2): S141-S143.
3. Di BAM,. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009; 49 (5 suppl): S56-S60.
4. Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008; 48: 137-145.
5. Hatanaka K, Kudo M, Fukunaga T, et al. Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCC. Intervirology. 2007; 50: 24-31.
6. El-Serag HB,. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007; 37 (suppl 2): S88-S94.
7. Starley BQ, Calcagno CJ, Harrison SA,. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010; 51: 1820-1832.
8. N'Kontchou G, Paries J, Htar MT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol. 2006; 4: 1062-1068.
9. Duan XY, Qiao L, Fan JG,. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11: 18-27.
10. Uetake S, Yamauchi M, Itoh S, et al. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res. 2003; 27 (8 suppl): 47S-51S.
11. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011; 9: 617-623.
12. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89: 500-507.
13. Matsumata T, Kanematsu T, Takenaka K, et al. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology. 1989; 9: 457-460.
14. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007; 141: 196-202.
15. Lerose R, Molinari R, Rocchi E, et al. Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer. 2001; 37: 239-245.
16. Abbas Z, Siddiqui AU, Luck NH, et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc. 2008; 58: 602-607.
17. Savci G,. The changing role of radiology in imaging liver tumors: an overview. Eur J Radiol. 1999; 32: 36-51.
18. Poon RT,. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 2009; 16: 792-794.
19. Iwamura K,. Capsule formation in hepatocellular carcinomas arising from liver cirrhosis [article in German]. Leber Magen Darm. 1988; 18: 56-60.
20. Ishigami K, Yoshimitsu K, Nishihara Y, et al. Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology. 2009; 250: 435-443.
21. Torimura T, Ueno T, Inuzuka S, et al. Mechanism of fibrous capsule formation surrounding hepatocellular carcinoma. Immunohistochemical study. Arch Pathol Lab Med. 1991; 115: 365-371.
22. Haratake J, Takeda S, Kasai T, et al. Predictable factors for estimating prognosis of patients after resection of hepatocellular carcinoma. Cancer. 1993; 72: 1178-1183.
23. Lam CM, Yong JL, Chan AO, et al. Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related. J Clin Gastroenterol. 2005; 39: 533-539.
24. Yeh SH, Chen PJ,. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010; 78 (suppl 1): 172-179.
25. Ng IO, Ng MM, Lai EC, et al. Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer. 1995; 75: 18-22.
26. Wu MH, Ma WL, Hsu CL, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010; 2: 32-35.
27. Friedman LS, Gang DL, Hedberg SE, et al. Simultaneous occurrence of hepatic adenoma and focal nodular hyperplasia: report of a case and review of the literature. Hepatology. 1984; 4: 536-540.
28. Nime F, Pickren JW, Vana J, et al. The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer. 1979; 44: 1481-1489.
29. Chen YJ, Chen PJ, Lee MC, et al. Chromosomal analysis of hepatic adenoma and focal nodular hyperplasia by comparative genomic hybridization. Genes Chromosomes Cancer. 2002; 35: 138-143.
30. Nagasue N, Ogawa Y, Yukaya H, et al. Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology. 1985; 88: 768-772.
31. Naugler WE, Karin M,. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14: 109-119.
32. Taketomi A, Takenaka K, Matsumata T, et al. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection. Hepatogastroenterology. 1997; 44: 477-483.
33. Pfeilschifter JKR, Pfohl MSH,. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002; 23: 90-119.
34. Rachon D, Mysliwska J, Suchecka-Rachon K, et al. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol. 2002; 172: 387-395.
35. Dai WS, Kuller LH, LaPorte RE, et al. The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol. 1981; 114: 804-816.
36. Kanda T, Steele R, Ray R, et al. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol. 2008; 82: 11066-11072.
37. Yang WJ, Chang CJ, Yeh SH, et al. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology. 2009; 49: 1515-1524.
38. Ueno M, Uchiyama K, Ozawa S, et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011; 18: 3624-3631.
39. Li T, Fan J, Qin LX, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011; 18: 1955-1963.
40. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 64-70.
41. Sakamoto M, Hirohashi S, Shimosato Y,. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol. 1991; 22: 172-178.
42. Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011; 46: 1230-1237.